Despite successful outcomes of different anti-TGF-β approaches in cell culture and animal models, cancer clinical trials utilizing strategies to block TGF-β signaling have demonstrated poor or inconsistent results so far [51], suggesting a crucial yet underexplored context-dependent role of TGF-β signaling in human cancers. The gene discussed is TGFB1; the disease is cancer.